Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
AstraZeneca
Colorcon
Moodys
Baxter

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for CHS-828

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for CHS-828?

CHS-828 is an investigational drug.

There have been 15 clinical trials for CHS-828. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2020.

The most common disease conditions in clinical trials are Psoriasis, Hyperemesis Gravidarum, and Arthritis, Rheumatoid. The leading clinical trial sponsors are Coherus Biosciences, Inc., Baxalta US Inc., and Daiichi Sankyo Co., Ltd.

There are eighteen US patents protecting this investigational drug and two hundred and sixty-two international patents.

Recent Clinical Trials for CHS-828
TitleSponsorPhase
Treatment Strategies in CHSCanadian Institutes of Health Research (CIHR)Phase 4
Treatment Strategies in CHSUniversity of CalgaryPhase 4
Improving Pain Control in Paraesophageal Hernia Repair: Intravenous Lidocaine Versus PlaceboAtrium HealthPhase 4

See all CHS-828 clinical trials

Clinical Trial Summary for CHS-828

Top disease conditions for CHS-828
Top clinical trial sponsors for CHS-828

See all CHS-828 clinical trials

US Patents for CHS-828

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CHS-828   Start Trial Compounds and compositions for the inhibition of NAMPT Forma TM, LLC (Watertown, MA) Genentech, Inc. (South San Francisco, CA)   Start Trial
CHS-828   Start Trial Compounds and compositions for the inhibition of NAMPT FORMA TM, LLC (Watertown, MA) Genentech, Inc. (South San Francisco, CA)   Start Trial
CHS-828   Start Trial Methods and compositions for treatment of demyelinating diseases Pathologica LLC (San Francisco, CA)   Start Trial
CHS-828   Start Trial N-cyano-N'-pyridylguanidines as serotonin antagonists Leo Pharmaceutical Products Ltd. (Ballerup, DK)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for CHS-828

Drugname Country Document Number Estimated Expiration Related US Patent
CHS-828 Argentina 082885 2030-09-03   Start Trial
CHS-828 Australia 2011295725 2030-09-03   Start Trial
CHS-828 Brazil 112013004773 2030-09-03   Start Trial
CHS-828 Canada 2810038 2030-09-03   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Dow
McKesson
Colorcon
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.